Aortic Thrombosis and Ischemic Stroke With Hemorrhagic Conversion in a Patient With Remote COVID-19 Infection: A Treatment Dilemma.

aortic mobile thrombus hypercoaguable in hospital cardiac arrest ischemic cerebrovascular disease post covid-19 sequelae

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
May 2022
Historique:
accepted: 23 05 2022
entrez: 27 6 2022
pubmed: 28 6 2022
medline: 28 6 2022
Statut: epublish

Résumé

Coronavirus disease 2019 (COVID-19) is primarily known to affect the lungs; however, several studies indicate that it can be a multisystem disease. There is documentation detailing different sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients affected with this virus have been seen to develop a hypercoagulable state leading to systemic thrombosis in some cases or embolism leading to catastrophic outcomes in others. Data regarding anticoagulation in these patients is limited. Further research needs to be carried out for management and prophylaxis for patients with COVID-19 at risk of aortic thrombosis.  We present a case of a middle-aged man with multiple comorbidities and remote COVID-19 infection who came to the emergency room with signs and symptoms worrisome for a cerebrovascular accident (CVA). Brain imaging revealed multiple cortical infarcts suggestive of a cardioembolic etiology. During his hospitalization, he underwent a transesophageal echocardiogram (TEE) that showed a 1x1 cm mobile thrombus in the distal descending aorta. Laboratory workup was negative for any hypercoagulable condition; it was thought that this patient might have a hypercoagulable state post-COVID-19 infection. After a thorough risk vs. benefit discussion, patient was started on apixaban. He remains alive and is doing well in a recent follow-up in our clinic.

Identifiants

pubmed: 35755513
doi: 10.7759/cureus.25272
pmc: PMC9218949
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e25272

Informations de copyright

Copyright © 2022, Riasat et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

QJM. 2021 Nov 13;114(9):619-620
pubmed: 33720351
Clin Infect Pract. 2021 Jan;9:100059
pubmed: 33521626
Clin Chem Lab Med. 2020 Jun 25;58(7):1116-1120
pubmed: 32172226
J Thromb Haemost. 2020 Jul;18(7):1548-1555
pubmed: 32329246
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620962853
pubmed: 33074732
JAMA Netw Open. 2020 Jun 1;3(6):e2011192
pubmed: 32501489
Thromb Res. 2020 Oct;194:101-115
pubmed: 32788101

Auteurs

Maria Riasat (M)

Internal Medicine, Icahn School of Medicine at Mount Sinai Beth Israel, New York, USA.

Arshan Khan (A)

Internal Medicine, Ascension St. John Hospital, Detroit, USA.

Moiz Ehtesham (M)

Internal Medicine, Albany Medical College, Albany, USA.

Syed Farrukh Mustafa (SF)

Cardiology, Icahn School of Medicine at Mount Sinai Beth Israel, New York, USA.

Natasha Qureshi (N)

Internal Medicine, Icahn School of Medicine at Mount Sinai Beth Israel, New York, USA.

Classifications MeSH